Pricing Log in Create free account
Saturday 17 October 2026 Export XCUR’s income statement to Excel — free account

Exicure, Inc.

XCUR Healthcare Biotechnology

Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022. In the quarter to June 2026, EPS grew 56.1% and free cash flow grew 65.4%, each against the same quarter a year earlier.

1.11 0.01 −0.89%
Market cap
$7.3M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
n/a
Altman Z
−18.31
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 11.58
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — 1 3 — — — — — — — — —
Insider Ownership 41.48%

Capital & Financial Ratios $m

Market Cap 7.33
Revenue 26.76
Net Income (8.28)
Free Cash Flow (6.70)
Net Debt (1.72)
Current Ratio 0.56 (below 1: weak)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.32) (negative: loss-making)
P/S ratio 0.26
P/B ratio 7.24 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth (67.04%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 1.2×; over the ten years it ranged from −25.2× in 2021 to 1,095× in 2018.
P/S against its own 10 years 22.24%
10-year low 10-year high
P/B against its own 10 years 78.43%
10-year low 10-year high
EV/Sales against its own 10 years 7.15%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1 13 4 2
Receivables 0 1 0 0
Inventory — — — —
Other — — — —
2 14 5 2
2023 2024 2025 Q'26
Payables 2 1 2 2
ST’ Debt — — — —
Other — — — —
3 3 4 4

Compound Annual Growth %

10y 5y 3y
Sales — 33.48% (68.89%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (42.32%) (35.92%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 1 — — — 1
’22 3 2 2 22 29
’21 1 0 (4) 2 0
’20 9 5 2 0 17
’19 0 0 1 0 1
’18 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (2) (2) (4) (1) (9)
’24 0 (1) 0 (1) (3)
’23 (3) (5) (1) (1) (10)
’22 (13) (9) (7) (7) (36)
’21 (15) (11) 5 (14) (35)
’20 (8) (11) (9) (12) (39)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (2) (3) (3) (1) (9)
’24 0 (1) 0 (1) (3)
’23 (3) (5) (1) 0 (9)
’22 (13) (9) (7) (7) (35)
’21 (15) (11) 5 (14) (36)
’20 (8) (13) (9) (12) (42)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.29) (0.18) — — —
’25 0.49 (0.41) (0.39) (0.46) (0.79)
’24 (0.50) (0.35) (0.57) (3.39) (4.75)
’23 (3.50) (3.40) (3.05) (0.65) (10.55)
’22 (10.51) (8.30) (5.20) 20.50 (2.80)
’21 (21.02) (24.02) (40.54) (22.52) (108.11)
’20 1.50 (7.51) (15.01) (22.52) (42.04)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 417.15 243.00 143.55 28.20 3.15 1.83 1.44 3.10

Analyst estimates 2026–2028

Powerpack
High — — 975.00 576.00 495.00 424.50 50.85 8.90 36.00 15.91
People
People Employees — 16 27 29 63 47 13 6 7 8
Revenue/emp, $m 0.00 0.61 0.00 0.04 0.26 (0.01) 2.22 0.00 0.07 0.00
Income, $m
Income, $m Revenue 1 10 0 1 17 0 29 — 1 —
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — 100.00 —
EBT (17) (11) (22) (26) (25) (64) (2) (17) (10) (6)
EBT margin, % (1,635.23) (113.29) (18,994.07) (2,029.55) (148.49) 13,271.64 (8.23) 0.00 (1,938.60) 0.00
Net income (17) (11) (22) (26) (25) (64) (3) (17) (10) (5)
Depreciation 0 0 0 1 2 2 2 1 1 0
Per share, $
Per share, $ Revenue 1,295.00 144.20 0.43 3.37 28.60 (0.82) 31.20 0.00 0.24 0.00
Earnings (22,510.56) (163.37) (81.70) (69.07) (42.04) (108.11) (2.80) (10.55) (4.75) (0.79)
Cash flow (6,312.50) (293.61) (71.04) 3.43 (67.61) (58.94) (38.60) (6.46) (1.42) (1.36)
Capex (492.50) (13.74) (0.34) (2.82) (5.46) (1.64) 0.21 0.58 0.00 0.01
Free cash flow (6,805.00) (307.34) (71.39) 0.61 (73.07) (60.57) (38.39) (5.89) (1.42) (1.35)
Book value 3,060.00 296.37 76.38 210.22 105.90 19.01 16.15 1.89 3.31 0.62
Shares, m 0 0 0 0 1 1 1 2 2 6
Valuation, ×
Valuation, × P/E 0.22 0.22 0.00 0.00 0.00 0.00 0.00 — 0.00 —
P/S 16.64 16.64 1,234.35 127.14 9.28 0.00 0.22 — 1.04 —
P/B 7.47 7.47 6.95 2.04 2.51 1.59 0.42 — 4.12 —
EV/Sales 14.42 14.42 1,095.22 45.54 5.35 14.42 0.18 — 0.85 —
EV/FCF (5.75) (5.75) (6.53) 251.14 (2.10) 0.19 (0.14) — (11.49) —
Cash, $m
Cash, $m Operating cash flow (5) (20) (19) 1 (39) (35) (36) (10) (3) (9)
Capex 0 (1) 0 (1) (3) (1) 0 1 — 0
Free cash flow (5) (21) (20) 0 (42) (36) (35) (9) (3) (9)
Balance, $m
Balance, $m Working capital 8 24 26 82 73 10 8 0 11 1
Total debt 6 5 5 5 17 7 7 — — —
Net debt (14) (21) (21) (106) (65) (32) (9) (1) (13) (4)
Shareholders’ equity 2 20 21 81 62 11 15 3 7 4
Returns, %
Returns, % ROA (68.36) (44.43) (77.63) (36.53) (22.87) (77.55) (5.86) (96.91) (72.84) (34.00)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 (18.04) (423.14) 0.00 (1,469.79)
ROE 167.67 108.98 (109.53) (51.73) (34.68) (176.25) (19.74) (188.43) (197.92) (92.47)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Mar 2024

Charts ten years each

Exicure, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SNGX Soligenix Inc. $7.7M — (loss-making) — (loss-making) −98.89% (below 0%: shrinking) n/m +37.83% (above 0%: growing) 0.00% 0.00% Compare
CURX Curanex Pharmaceuticals Inc $7.6M — (loss-making) — — n/m −272.32% (below 0%: shrinking) — 0.00% Compare
MBRX Moleculin Biotech, Inc. $7.6M 0.0× — — n/m −19.26% (below 0%: shrinking) 0.00% 0.00% Compare
CALC CalciMedica Inc. $7.4M — (loss-making) — — n/m +31.42% (above 0%: growing) 0.00% 0.00% Compare
XCUR Exicure, Inc. $7.3M — (loss-making) — (loss-making) −80.51% (below 0%: shrinking) n/m +65.38% (above 0%: growing) 100.00% 0.00%
SKYE Skye Bioscience, Inc. $7.0M — (loss-making) — −34.71% (below 0%: shrinking) n/m +34.84% (above 0%: growing) 72.71% 0.00% Compare
BCLI Brainstorm Cell Therapeutics Inc. $7.0M — (loss-making) — — n/m +74.44% (above 0%: growing) 0.00% 0.00% Compare
CLGN CollPlant Biotechnologies Ltd. Sponsored ADR $7.0M — (loss-making) — (loss-making) −39.66% (below 0%: shrinking) n/m +5.08% (above 0%: growing) (422.22%) (2,437.96%) Compare
NIKI Niki BioSolutions, Inc. $6.9M — (loss-making) 31.9× −32.36% (below 0%: shrinking) +69.51% (above 0%: growing) +58.14% (above 0%: growing) (154.22%) 0.00% Compare
Median of peers $7.2M — — −37.18% — +33.13% 0.00% 0.00%

All 614 Biotechnology stocks →

Exicure, Inc. (XCUR) key facts

  • Concern: Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022.
  • Exicure, Inc. (XCUR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, XCUR traded at $1.11, a market capitalization of $7.3 million.
  • Return on equity was −92.5% and debt-to-equity 0.00.
  • Its Altman Z-score is −18.31 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.

Exicure, Inc. (XCUR) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/XCUR · Data as of Mar 31, 2024 · For information only; not investment advice. · © 2026 stockrow.com